Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Safety Labeling Change Guidance Seeks To Ease Class Confusion

Executive Summary

Final guidance implementing FDAAA authority explains how disagreements between the agency and one or more sponsors could affect the timeline for safety-related labeling changes across a class of products.


Related Content

Opioid Indication Change Could Draw Legal Challenge From Physicians Group Seeking More Restrictions
FDA Labeling Change Rule Is Most Prominent Item On Agency’s To-Do List
With New Power, New Problems: FDA Confronts Complications of Safety Labeling Change Authority
Industry Seeks Power To Trigger Safety Labeling Changes Under FDAAA
Class-Wide Rx Safety Issues Are Focus Of FDA Guidance On New Label Change Powers





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts